# A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

> **NCT05693935** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 675 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** TV-44749
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05693935
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-24
- **Primary completion:** 2024-03-19
- **Final completion:** 2025-01-27
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05693935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05693935, "A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05693935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*